2024年12月25日 · PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha) is a Protein Coding gene. Diseases associated with PIK3CA include Megalencephaly-Capillary Malformation-Polymicrogyria Syndrome and Congenital Lipomatous Overgrowth, Vascular Malformations, And Epidermal Nevi.

The phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (the HUGO-approved official symbol = PIK3CA; HGNC ID, HGNC:8975), also called p110α protein, is a class I PI 3-kinase catalytic subunit.

2025年3月3日 · PIK3CA-related overgrowth spectrum (PROS) includes a group of genetic disorders that leads to overgrowth of various body parts due to changes (variants) in the gene PIK3CA. This gene is involved in making a protein that helps regulate cell …

The PIK3CA gene provides instructions for making the p110 alpha (p110α) protein, which is one piece (subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3K). Learn about this gene and related health conditions.

2021年3月22日 · One type of gene mutation that’s known to affect people with breast cancer is called PIK3CA. A mutation in the PIK3CA gene can cause cells to divide and replicate uncontrollably. It contributes...

2013年8月15日 · PIK3CA-related overgrowth spectrum (PROS) encompasses a range of clinical findings in which the core features are congenital or early-childhood onset of segmental/focal overgrowth with or without cellular dysplasia.

3 天之前 · PIK3CA mutations influence breast cancer progression by shaping tumor growth dynamics, metastatic potential, and treatment resistance. While often associated with a luminal phenotype and well-differentiated histopathology, their impact on disease trajectory depends on context. In HR+ breast cancers, PIK3CA alterations contribute to sustained ...

PIK3CA is a crucial player in the PI3K/AKT signaling pathway that regulates essential cellular processes like growth, survival, and proliferation. It is estimated that PIK3CA mutations occur in approximately 30% of all breast cancer cases , with varying mutation rates across different molecular subtypes .

4 天之前 · Turner NC, Im S-A, Saura C, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391(17):1584-1596. U.S. Food and Drug Administration. FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.

A gene that makes one of the proteins in an enzyme called PI3K, which is involved in many important functions in a cell. Mutations (changes) in the PIK3CA gene may cause the PI3K enzyme to become overactive, which may cause cancer cells to grow.